$1.91
5.52% yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US09060U5074
Symbol
BCDA

BioCardia Inc. Stock News

Neutral
Seeking Alpha
11 days ago
BioCardia, Inc. (NASDAQ:BCDA ) Q2 2025 Earnings Conference Call August 11, 2025 7:00 AM ET Company Participants David McClung - Chief Financial Officer Miranda Peto Benvenuti - Corporate Participant Peter A. Altman - CEO, President & Director Conference Call Participants James Francis Molloy - Alliance Global Partners, Research Division Kumaraguru Raja - Brookline Capital Markets, LLC, Research...
Neutral
GlobeNewsWire
11 days ago
SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2025 with the Securities and Exchange Commissi...
Neutral
GlobeNewsWire
16 days ago
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following ma...
Neutral
GlobeNewsWire
19 days ago
SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provides the anticipated timing of regulatory activities seeking FDA and Japan PMDA approvals of its CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter.
Neutral
GlobeNewsWire
3 months ago
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia's CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Direc...
Neutral
Seeking Alpha
3 months ago
Start Time: 16:30 January 1, 0000 5:01 PM ET BioCardia, Inc. (NASDAQ:BCDA ) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Company Participants Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Conference Call Participants Joe Pantginis - H.C. Wainwright Laura Suriel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
Neutral
GlobeNewsWire
3 months ago
SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The C...
Neutral
GlobeNewsWire
4 months ago
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following m...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today